71675-90-6
Chemical Structure
Aramisulpride
Synonym(s): (R)-Amisulpride;(R)-Esamisulpride;(R)-DAN 2163
- CAS No.: 71675-90-6
- Formula:C17H27N3O4S
- Molecular Weight:369.48
IUPAC Name: (R)-4-amino-N-((1-ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide
InChIKey: NTJOBXMMWNYJFB-GFCCVEGCSA-N
SMILES: O=C(NC[C@@H]1N(CC)CCC1)C2=CC(S(=O)(CC)=O)=C(N)C=C2OC
Biological Activity: Aramisulpride (R-(+)-Amisulpride) is the R-isomer of Amisulpride (HY-14545). Aramisulpride is a 5-HT7 receptor antagonist with a Ki value of 22 nM. Aramisulpride is a D2/D3 receptor antagonist with a Ki value of 140 nM for D2R and a Ki value of 13.9 nM for D3R. Aramisulpride can be used in psychiatric research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Aramisulpride | 98.49% | Aramisulpride (R-(+)-Amisulpride) is the R-isomer of Amisulpride (HY-14545). Aramisulpride is a 5-HT7 receptor antagonist with a Ki value of 22 nM. Aramisulpride is a D2/D3 receptor antagonist with a Ki value of 140 nM for D2R and a Ki value of 13.9 nM for D3R. Aramisulpride can be used in psychiatric research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Aramisulpride (Standard) | ≥98% | Aramisulpride (Standard) is the analytical standard of Aramisulpride (HY-109167). This product is intended for research and analytical applications. Aramisulpride (R-(+)-Amisulpride) is the R-isomer of Amisulpride (HY-14545). Aramisulpride is a 5-HT7 receptor antagonist with a Ki value of 22 nM. Aramisulpride is a D2/D3 receptor antagonist with a Ki value of 140 nM for D2R and a Ki value of 13.9 nM for D3R. Aramisulpride can be used in psychiatric research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Vincent Grattan, et al. Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7. ACS Omega. 2019 Aug 15;4(9):14151-14154. [Content Brief]
- [2]. Hopkins SC, et al. Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders. Clin Pharmacol Ther. 2021 Sep;110(3):808-815. [Content Brief]
